Fiche centre
Massachusetts General Hospital
Boston — United States
Essais liés93clinical trials
VilleBostonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05076838
Essais cliniques associés
93| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Evolocumab | Maladie coronarienne | Phase 4 | NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | ACTIVE_NOT_RECRUITING |
| Percutaneous Mechanical Circulatory Support | Maladie coronarienne | Non applicable | NCT06445608 | PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | RECRUITING |
| imlifidase | SEP | Phase 3 | NCT04935177 | ConfIdeS — Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx | COMPLETED |
| BrioVAD System | Insuffisance cardiaque | Non applicable | NCT06310031 | INNOVATE — Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | ACTIVE_NOT_RECRUITING |
| OPTIMIZER® Integra CCM-D System (Treatment Arm) | Maladie coronarienne | Non applicable | NCT05855135 | INTEGRA-D — Assessment of Combined CCM and ICD Device in HFrEF | ACTIVE_NOT_RECRUITING |
| Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System | Maladie coronarienne | Non applicable | NCT07308847 | Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | ACTIVE_NOT_RECRUITING |
| Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System | Maladie coronarienne | Non applicable | NCT06779630 | BIOFLOW-48 — Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | RECRUITING |
| Dapagliflozin (10Mg Tab) along with standard medical therapy | Lupus | Phase 4 | NCT07323524 | Dapa-Active LN — Dapagliflozin in Active Lupus Nephritis | RECRUITING |
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| transcutaneous vagus nerve stimulation | Myopathies | Non applicable | NCT07904351 | R61VNS — Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation | NOT_YET_RECRUITING |
| zagociguat 15mg | Myopathies | Phase 2 | NCT06961344 | An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) | TERMINATED |
| Active tPBM-2.0 | Alzheimer | Phase 2 | NCT04784416 | Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) | COMPLETED |
| taVNS | SEP | Non applicable | NCT03603730 | Vagal Nerve Stimulation for Interoception Modulation | COMPLETED |
| Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System | Insuffisance cardiaque | Non applicable | NCT05064709 | AIM HIGHer — Assessment of CCM in HF With Higher Ejection Fraction | RECRUITING |
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | Non applicable | NCT06735534 | ReMATCH — Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | ACTIVE_NOT_RECRUITING |
| IV acetaminophen | Maladie coronarienne | Phase 3 | NCT04093219 | PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients | COMPLETED |
| Eplerenone | Maladie coronarienne | Phase 2/3 | NCT07892664 | SUNRISE HIV — Reducing Arterial Inflammation Using Eplerenone and Statins in HIV | NOT_YET_RECRUITING |
| Relative Blood Volume Monitoring (RBVM) | Maladie rénale chronique | À vérifier | NCT07866872 | Blood Volume Monitoring Via Critline in Volume Overload: Hospitalization and Readmission | ENROLLING_BY_INVITATION |
| Venetoclax | Maladie rénale chronique | Phase 1 | NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | RECRUITING |
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| WATCHMAN FLX LAAC Device | Accident vasculaire cérébral | Non applicable | NCT04394546 | CHAMPION-AF Clinical Trial | ACTIVE_NOT_RECRUITING |
| SherpaPak Cardiac Transport System | Insuffisance cardiaque | À vérifier | NCT04141605 | GUARDIAN — Global Utilization And Registry Database for Improved heArt preservatioN | ENROLLING_BY_INVITATION |
| IVC Sensor | Insuffisance cardiaque | Non applicable | NCT07574593 | NORM-HF Pivotal Study | RECRUITING |
| Investigational PFO Closure Device | Accident vasculaire cérébral | Non applicable | NCT05069558 | OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | ACTIVE_NOT_RECRUITING |
| zagociguat 15mg | Accident vasculaire cérébral | Phase 2 | NCT06402123 | PRIZM — A Phase 2b Study of Zagociguat in Patients With MELAS | COMPLETED |
| F-18 3F4AP | SEP | Phase 1 | NCT04699747 | Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects | RECRUITING |
| Filgrastim | SEP | Phase 3 | NCT00003595 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma | COMPLETED |
| LAM-002A | Sclérose latérale amyotrophique | Phase 2 | NCT05163886 | Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis | COMPLETED |
| RAPA-501 Autologous T stem cells | Sclérose latérale amyotrophique | Phase 2/3 | NCT04220190 | RAPA-501 Therapy for ALS | RECRUITING |
| T-DM1 | Cancer | Phase 2 | NCT02326974 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02637856 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Diazepam Nasal Spray [Valtoco] | Épilepsie | Phase 1/2 | NCT05076838 | Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy | COMPLETED |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| JSB462 | Cancer | Phase 2 | NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING |
| RNS System | Épilepsie | Phase 2 | NCT05339126 | RNS System LGS Feasibility Study | ACTIVE_NOT_RECRUITING |
| Theophylline | SEP | Phase 4 | NCT03718403 | Effect of Theophylline in Pseudohypoparathyroidism | RECRUITING |
| transcutaneous vagus nerve stimulation | Myopathies | Non applicable | NCT06009159 | Vagus Nerve Stimulation(VNS) As Treatment For Fibromyalgia Patients | RECRUITING |
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Computer-Assisted Microwave Liver Ablation | Cancer | Non applicable | NCT07226869 | MWA Sim — Computer Guided Microwave Liver Ablation | RECRUITING |
| Encorafenib | Cancer | Phase 3 | NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | ACTIVE_NOT_RECRUITING |
| TRI-611 | Cancer | Phase 1/2 | NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | RECRUITING |
| Optimal Stimulation Parameters to Disrupt Epileptiform Activity | Épilepsie | Non applicable | NCT06141668 | Optimal Stimulation Parameters to Disrupt Epileptiform Activity | COMPLETED |
| Supporting Our Caregivers In ADRD Learning (SOCIAL) | Alzheimer | Non applicable | NCT06276023 | Supporting Our Caregivers In ADRD Learning (SOCIAL) | COMPLETED |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| Tofersen | Sclérose latérale amyotrophique | Phase 2 | NCT07294144 | Tofersen in Non-SOD1 ALS | RECRUITING |
| Placement of the BrainGate2 sensor(s) into the motor-related cortex | Myopathies | Non applicable | NCT00912041 | BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia | RECRUITING |
| PF-07799544 | Cancer | Phase 1 | NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | RECRUITING |
| Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | À vérifier | NCT07110454 | DETECT LTFU — Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up | RECRUITING |
| Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | Non applicable | NCT07110337 | DETECT — Diagnosing Epilepsy To EffeCT Change | RECRUITING |
| GBPDC: Gut-Brain in PD Consortium Master Protocol | Parkinson | À vérifier | NCT07567794 | GBPDC: Gut-Brain in PD Consortium Master Protocol | RECRUITING |
| Edaravone (Radicava®/Radicava ORS®) | Sclérose latérale amyotrophique | À vérifier | NCT04259255 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | COMPLETED |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Foralumab Nasal | Sclérose latérale amyotrophique | Phase 2 | NCT07688239 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | ENROLLING_BY_INVITATION |
| EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | Myasthénie | À vérifier | NCT06002945 | EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | COMPLETED |
| Proximal Splenic Artery Embolization | Hypertension | Non applicable | NCT07755059 | Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis | NOT_YET_RECRUITING |
| AAV9-hSyn1-miGRIK2 | Épilepsie | Phase 1/2 | NCT06063850 | GenTLE — AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| ION363 | Sclérose latérale amyotrophique | Phase 3 | NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | ACTIVE_NOT_RECRUITING |
| XT-150 | Sclérose latérale amyotrophique | Phase 1 | NCT06704347 | Safety Study of XT-150 in Participants With ALS | NOT_YET_RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| COYA 302 | Sclérose latérale amyotrophique | Phase 2/3 | NCT07161999 | ALSTARS — Study of COYA 302 for the Treatment of ALS | ACTIVE_NOT_RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | À vérifier | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | RECRUITING |
| Iptacopan | Myasthénie | Phase 3 | NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | ACTIVE_NOT_RECRUITING |
| Inebilizumab | Lupus | Phase 2 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | RECRUITING |
| silevertinib in combination with temozolomide | Cancer | Phase 2 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | RECRUITING |
| M1774 | Cancer | Phase 1 | NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | ACTIVE_NOT_RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | Non applicable | NCT05820087 | The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) | ACTIVE_NOT_RECRUITING |
| Actual device PFO closure | Migraine | Non applicable | NCT04100135 | RELIEF — GORE® CARDIOFORM Septal Occluder Migraine Clinical Study | TERMINATED |
| zorevunersen | Épilepsie | Phase 3 | NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | ACTIVE_NOT_RECRUITING |
| EEG | Épilepsie | Non applicable | NCT06934356 | Subcortical Arousal in Perceptual Awareness | RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01892722 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT05285891 | AMS05 — Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Relaxation Response Training to Treat Hypertension | Hypertension | NA | NCT01263743 | Relaxation Response Training to Treat Hypertension | COMPLETED |
| A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy | Cancer | NA | NCT03310918 | A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy | ACTIVE_NOT_RECRUITING |
| Paradise Ultrasound Renal Denervation Treatment | Hypertension | À vérifier | NCT06297291 | US GPS — Global Paradise System US Post Approval Study | RECRUITING |
| The Paradise® Renal Denervation Ultrasound System | Hypertension | Non applicable | NCT02649426 | RADIANCE-HTN — A Study of the ReCor Medical Paradise System in Clinical Hypertension | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 2 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | RECRUITING |
| BrainGate Neural Interface System | Sclérose latérale amyotrophique | Non applicable | NCT05724173 | BG-Speech-01 — Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| GLPG1690 | SEP | Phase 2 | NCT03798366 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| eculizumab | Myasthénie | Phase 2 | NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | TERMINATED |
| RNS® System | Épilepsie | Phase 4 | NCT00572195 | RNS® System LTT Study | COMPLETED |